<?xml version="1.0" encoding="UTF-8" ?><rss 
        version         = "2.0"
        xmlns:content   = "http://purl.org/rss/1.0/modules/content/"
        xmlns:wfw       = "http://wellformedweb.org/CommentAPI/"
        xmlns:dc        = "http://purl.org/dc/elements/1.1/"
        xmlns:atom      = "http://www.w3.org/2005/Atom"
        xmlns:sy        = "http://purl.org/rss/1.0/modules/syndication/"
        xmlns:slash     = "http://purl.org/rss/1.0/modules/slash/"
        type            = "0"
                >
        <channel><item post_id='88169'><title>NUVISAN erhält Zuwendung in Höhe von 9,6 Mio. USD für ein Multi-Target-Wirkstoffforschungsprogramm für neuartige nicht-hormonelle Verhütungsmittel</title><link>https://business24.ch/2022/09/23/nuvisan-erhaelt-zuwendung-in-hoehe-von-96-mio-usd-fuer-ein-multi-target-wirkstoffforschungsprogramm-fuer-neuartige-nicht-hormonelle-verhuetungsmittel/</link><pubDate>Fri, 23 Sep 2022 10:00:02 +0000</pubDate>		<category><![CDATA[Presseportal]]></category>
		<category><![CDATA[noinjection]]></category>
<guid isPermalink='false'>https://business24.ch/?p=88169</guid><post-id xmlns="com-wordpress:feed-additions:1">88169</post-id></item></channel>
      </rss>